Mohamed Ismail Abdul Aziz

Cost utility analysis of tisagenlecleucel vs salvage chemotherapy in the treatment of relapsed/refractory diffuse large B-cell lymphoma from Singapore’s healthcare system perspective

Boon Piang Cher, Kar Yee Gan, Mohamed Ismail Abdul Aziz et al. · Journal of Medical Economics · 2020 · 32 citations · Full text

Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective

Ping-Tee Tan, Mohamed Ismail Abdul Aziz, Fiona Pearce et al. · BMC Cancer · 2018 · 23 citations · Full text

Gingival crevicular fluid bone morphogenetic protein-2 release profile following the use of modified perforated membrane barriers in localized intrabony defects: a randomized clinical trial.

Ahmed Gamal, Mohamed Ismail Abdul Aziz, Mohamed H. Salama et al. · PubMed · 2014 · 22 citations

Cost-effectiveness analysis of osimertinib for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small cell lung cancer in Singapore

Mohamed Ismail Abdul Aziz, Wayne Foo, Chee‐Keong Toh et al. · Journal of Medical Economics · 2020 · 22 citations · Full text

Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore

Sil-ling Pruis, Mohamed Ismail Abdul Aziz, Fiona Pearce et al. · International Journal of Technology Assessment in Health Care · 2019 · 21 citations · Full text